Patents by Inventor Steven G. Elliott
Steven G. Elliott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8268588Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.Type: GrantFiled: June 24, 2011Date of Patent: September 18, 2012Assignee: Amgen Inc.Inventors: Joan C. Egrie, Steven G. Elliott, Jeffrey K. Browne, Karen C. Sitney
-
Publication number: 20110256586Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.Type: ApplicationFiled: June 24, 2011Publication date: October 20, 2011Inventors: Joan C. Egrie, Steven G. Elliott, Jeffrey K. Browne, Karen C. Sitney
-
Patent number: 7977311Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.Type: GrantFiled: October 26, 2007Date of Patent: July 12, 2011Assignee: Amgen Inc.Inventors: Joan C. Egrie, Steven G. Elliott, Jeffrey K. Browne, Karen C. Sitney
-
Patent number: 7973009Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythropoietin analogs, methods of production of the analogs, and compositions comprising the analogs.Type: GrantFiled: October 26, 2007Date of Patent: July 5, 2011Assignee: Amgen Inc.Inventors: Joan C. Egrie, Steven G. Elliott, Jeffrey K. Browne, Karen C. Sitney
-
Publication number: 20090023636Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.Type: ApplicationFiled: October 26, 2007Publication date: January 22, 2009Inventors: Joan C. Egrie, Steven G. Elliott, Jeffrey K. Browne, Karen C. Sitney
-
Publication number: 20090017137Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythropoietin analogs, methods of production of the analogs, and compositions comprising the analogs.Type: ApplicationFiled: October 26, 2007Publication date: January 15, 2009Inventors: Joan C. Egrie, Steven G. Elliott, Jeffrey K. Browne, Karen C. Sitney
-
Publication number: 20080182976Abstract: Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.Type: ApplicationFiled: October 30, 2007Publication date: July 31, 2008Inventor: Steven G. Elliott
-
Patent number: 7399833Abstract: MGDF analogs having one or more changed glycosylation sites as compared to a naturally occurring MGDF sequence of a corresponding number of amino acids are disclosed. The invention also relates to DNA sequences encoding said MGDF analogs, recombinant plasmids and host cells for analog expression, and therapeutic compositions including such analogs.Type: GrantFiled: May 25, 1995Date of Patent: July 15, 2008Inventor: Steven G. Elliott
-
Patent number: 7304150Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.Type: GrantFiled: November 27, 2000Date of Patent: December 4, 2007Assignee: Amgen Inc.Inventors: Joan C. Egrie, Steven G. Elliott, Jeffrey K. Browne, Karen C. Sitney
-
Patent number: 7217689Abstract: Erythropoietin analogs having at least one additional site for glycosylation, or a rearrangement of at least one site for glycosylation are disclosed. The invention also relates to DNA sequences encoding said erythropoietin analogs, and recombinant plasmids and host cells for analog expression.Type: GrantFiled: June 6, 1995Date of Patent: May 15, 2007Assignee: Amgen Inc.Inventors: Steven G. Elliott, Thomas E. Byrne
-
Publication number: 20030215444Abstract: Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.Type: ApplicationFiled: February 10, 2003Publication date: November 20, 2003Applicant: Amgen Inc.Inventor: Steven G. Elliott
-
Publication number: 20030171541Abstract: The present invention provides G-Protein Coupled Receptor (GPCR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing GPCR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with GPCR polypeptides.Type: ApplicationFiled: February 14, 2002Publication date: September 11, 2003Applicant: Amgen Inc., A Corporation of the State of DelawareInventors: Steven G. Elliott, Norma Rogers, Leigh Anne Busse
-
Patent number: 6319499Abstract: Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.Type: GrantFiled: June 5, 1998Date of Patent: November 20, 2001Assignee: Amgen Inc.Inventor: Steven G. Elliott
-
Patent number: 5989538Abstract: Mpl ligand analogs having one or more changed glycosylation sites as compared to a naturally occurring mpl ligand sequence of a corresponding number of amino acids are disclosed. The invention also relates to DNA sequences encoding mpl ligand analogs, recombinant plasmids and host cells for analog expression, and therapeutic compositions including such analogs.Type: GrantFiled: September 11, 1997Date of Patent: November 23, 1999Assignee: Amgen Inc.Inventor: Steven G. Elliott
-
Patent number: 5885574Abstract: Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.Type: GrantFiled: July 26, 1994Date of Patent: March 23, 1999Assignee: Amgen Inc.Inventor: Steven G. Elliott
-
Patent number: 5756083Abstract: Mpl ligand analogs having one or more changed glycosylation sites as compared to a naturally occurring mpl ligand sequence of a corresponding number of amino acids are disclosed. The invention also relates to DNA sequences encoding mpl ligand analogs, recombinant plasmids and host cells for analog expression, and therapeutic compositions including such analogs.Type: GrantFiled: February 9, 1996Date of Patent: May 26, 1998Assignee: Amgen Inc.Inventor: Steven G. Elliott
-
Patent number: 5696250Abstract: MGDF analogs having one or more changed glycosylation sites as compared to a naturally occuring MGDF sequence of a corresponding number of amino acids are disclosed. The invention also relates to DNA sequences encoding said MGDF analogs, recombinant plasmids and host cells for analog expression, and therapeutic compositions including such analogs.Type: GrantFiled: February 15, 1995Date of Patent: December 9, 1997Assignee: Amgen Inc.Inventor: Steven G. Elliott